Annual Operating Profit
-$138.04 M
+$23.63 M+14.62%
31 December 2023
Summary:
Adaptimmune Therapeutics annual operaing income is currently -$138.04 million, with the most recent change of +$23.63 million (+14.62%) on 31 December 2023. During the last 3 years, it has fallen by -$4.63 million (-3.47%). ADAP annual operating profit is now -1376.23% below its all-time high of -$9.35 million, reached on 30 June 2013.ADAP Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Operating Profit
-$14.68 M
-$83.38 M-121.37%
30 September 2024
Summary:
Adaptimmune Therapeutics quarterly operating income is currently -$14.68 million, with the most recent change of -$83.38 million (-121.37%) on 30 September 2024. Over the past year, it has increased by +$31.95 million (+68.52%). ADAP quarterly operating profit is now -121.37% below its all-time high of $68.70 million, reached on 30 June 2024.ADAP Quarterly Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Operating Profit
-$45.10 M
+$31.95 M+41.47%
30 September 2024
Summary:
Adaptimmune Therapeutics TTM operating income is currently -$45.10 million, with the most recent change of +$31.95 million (+41.47%) on 30 September 2024. Over the past year, it has increased by +$68.03 million (+60.14%). ADAP TTM operating profit is now -1029.71% below its all-time high of -$3.99 million, reached on 30 September 2014.ADAP TTM Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ADAP Operating Profit Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +14.6% | +68.5% | +60.1% |
| 3 y3 years | -3.5% | +65.2% | +71.3% |
| 5 y5 years | -67.6% | +63.4% | +68.1% |
ADAP Operating Profit High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -3.5% | +14.9% | -121.4% | +70.6% | at high | +76.3% |
| 5 y | 5 years | -67.6% | +14.9% | -121.4% | +70.6% | at high | +76.3% |
| alltime | all time | -1376.2% | +14.9% | -121.4% | +70.6% | -1029.7% | +76.3% |
Adaptimmune Therapeutics Operating Profit History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$14.68 M(-121.4%) | -$45.10 M(-41.5%) |
| June 2024 | - | $68.70 M(-239.5%) | -$77.05 M(-59.6%) |
| Mar 2024 | - | -$49.26 M(-1.2%) | -$190.66 M(+38.1%) |
| Dec 2023 | -$138.04 M(-14.6%) | -$49.86 M(+6.9%) | -$138.04 M(+22.0%) |
| Sept 2023 | - | -$46.63 M(+3.8%) | -$113.13 M(+3.3%) |
| June 2023 | - | -$44.91 M(-1436.9%) | -$109.48 M(+1.1%) |
| Mar 2023 | - | $3.36 M(-113.5%) | -$108.33 M(-33.0%) |
| Dec 2022 | -$161.67 M(-0.4%) | -$24.95 M(-42.0%) | -$161.67 M(-10.0%) |
| Sept 2022 | - | -$42.99 M(-1.7%) | -$179.59 M(+0.5%) |
| June 2022 | - | -$43.75 M(-12.5%) | -$178.78 M(+2.5%) |
| Mar 2022 | - | -$49.98 M(+16.6%) | -$174.34 M(+7.5%) |
| Dec 2021 | -$162.25 M(+21.6%) | -$42.86 M(+1.6%) | -$162.25 M(+3.4%) |
| Sept 2021 | - | -$42.18 M(+7.3%) | -$156.90 M(+4.2%) |
| June 2021 | - | -$39.31 M(+3.8%) | -$150.59 M(+6.4%) |
| Mar 2021 | - | -$37.89 M(+1.0%) | -$141.53 M(+6.1%) |
| Dec 2020 | -$133.41 M(-4.6%) | -$37.51 M(+4.6%) | -$133.41 M(+5.7%) |
| Sept 2020 | - | -$35.88 M(+18.6%) | -$126.25 M(-3.3%) |
| June 2020 | - | -$30.25 M(+1.6%) | -$130.49 M(-3.9%) |
| Mar 2020 | - | -$29.76 M(-1.9%) | -$135.74 M(-2.9%) |
| Dec 2019 | -$139.77 M | -$30.36 M(-24.3%) | -$139.77 M(-1.2%) |
| Sept 2019 | - | -$40.12 M(+13.0%) | -$141.52 M(+49.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2019 | - | -$35.50 M(+5.1%) | -$94.38 M(+7.5%) |
| Mar 2019 | - | -$33.79 M(+5.3%) | -$87.76 M(+6.1%) |
| Dec 2018 | -$82.36 M(+2.1%) | -$32.11 M(-557.5%) | -$82.70 M(+3.0%) |
| Sept 2018 | - | $7.02 M(-124.3%) | -$80.30 M(-13.0%) |
| June 2018 | - | -$28.88 M(+0.5%) | -$92.28 M(+5.8%) |
| Mar 2018 | - | -$28.74 M(-3.2%) | -$87.18 M(+8.1%) |
| Dec 2017 | -$80.66 M(+10.8%) | -$29.70 M(+498.8%) | -$80.66 M(+22.9%) |
| Sept 2017 | - | -$4.96 M(-79.1%) | -$65.62 M(-17.2%) |
| June 2017 | - | -$23.78 M(+7.0%) | -$79.28 M(+1.4%) |
| Mar 2017 | - | -$22.22 M(+51.6%) | -$78.19 M(+7.4%) |
| Dec 2016 | -$72.80 M(+175.6%) | -$14.66 M(-21.3%) | -$72.80 M(+25.2%) |
| Sept 2016 | - | -$18.62 M(-18.0%) | -$58.14 M(+16.7%) |
| June 2016 | - | -$22.70 M(+34.9%) | -$49.82 M(+83.7%) |
| Mar 2016 | - | -$16.82 M(+63.4%) | -$27.12 M(+89.3%) |
| Dec 2015 | -$26.41 M(+7.2%) | - | - |
| Sept 2015 | - | -$10.30 M(+155.3%) | -$14.33 M(+78.6%) |
| June 2015 | -$24.64 M(+113.9%) | - | - |
| Dec 2014 | - | -$4.03 M(+1.0%) | -$8.03 M(+101.0%) |
| Sept 2014 | - | -$3.99 M | -$3.99 M |
| June 2014 | -$11.52 M(+23.2%) | - | - |
| June 2013 | -$9.35 M | - | - |
FAQ
- What is Adaptimmune Therapeutics annual operaing income?
- What is the all time high annual operating profit for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics annual operating profit year-on-year change?
- What is Adaptimmune Therapeutics quarterly operating income?
- What is the all time high quarterly operating profit for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics quarterly operating profit year-on-year change?
- What is Adaptimmune Therapeutics TTM operating income?
- What is the all time high TTM operating profit for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics TTM operating profit year-on-year change?
What is Adaptimmune Therapeutics annual operaing income?
The current annual operating profit of ADAP is -$138.04 M
What is the all time high annual operating profit for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high annual operaing income is -$9.35 M
What is Adaptimmune Therapeutics annual operating profit year-on-year change?
Over the past year, ADAP annual operaing income has changed by +$23.63 M (+14.62%)
What is Adaptimmune Therapeutics quarterly operating income?
The current quarterly operating profit of ADAP is -$14.68 M
What is the all time high quarterly operating profit for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high quarterly operating income is $68.70 M
What is Adaptimmune Therapeutics quarterly operating profit year-on-year change?
Over the past year, ADAP quarterly operating income has changed by +$31.95 M (+68.52%)
What is Adaptimmune Therapeutics TTM operating income?
The current TTM operating profit of ADAP is -$45.10 M
What is the all time high TTM operating profit for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high TTM operating income is -$3.99 M
What is Adaptimmune Therapeutics TTM operating profit year-on-year change?
Over the past year, ADAP TTM operating income has changed by +$68.03 M (+60.14%)